CHC — Investor Presentation 2016

Oct 19, 2016

==> picture [594 x 127] intentionally omitted <==

==> picture [128 x 127] intentionally omitted <==

==> picture [452 x 57] intentionally omitted <==

2016 Institutional Investor Conference 4164 TT

==> picture [81 x 54] intentionally omitted <==

==> picture [122 x 47] intentionally omitted <==

==> picture [97 x 39] intentionally omitted <==

==> picture [61 x 36] intentionally omitted <==

==> picture [123 x 34] intentionally omitted <==

==> picture [104 x 48] intentionally omitted <==

==> picture [105 x 26] intentionally omitted <==

==> picture [80 x 24] intentionally omitted <==

==> picture [119 x 21] intentionally omitted <==

==> picture [84 x 18] intentionally omitted <==

==> picture [72 x 22] intentionally omitted <==

==> picture [150 x 54] intentionally omitted <==

Disclaimer

• The information contained in this confidential document ("Presentation") has been prepared by CHC Healthcare Group (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.

• While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

• Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

• This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

• This Presentation includes certain statements that may be deemed “forward-looking statements”. All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

2

==> picture [594 x 124] intentionally omitted <==

==> picture [128 x 124] intentionally omitted <==

==> picture [519 x 160] intentionally omitted <==

----- Start of picture text -----

Company Operational Future
Q & A
Overview Results Guidance
----- End of picture text -----

==> picture [144 x 33] intentionally omitted <==

3

==> picture [594 x 124] intentionally omitted <==

==> picture [128 x 124] intentionally omitted <==

==> picture [520 x 236] intentionally omitted <==

----- Start of picture text -----

Company Operational Future
Q & A
Overview Results Guidance
----- End of picture text -----

==> picture [144 x 33] intentionally omitted <==

4

Company Introduction

• Name ： CHC Healthcare Group (4164 TT)

• Date of Establish ： 2009/11/27

• (First subsidiary, Chiu Ho Medical, was founded on 1977/08/12.)

• Chairman ： Mr. Lee Pei-Lin

• Headquarters ： Taipei

• Branches ： Taichung, Kaohsiung, Beijing & Guangzhou

• Major Business ： Providing Medical Equipment Full Service Solutions

• • Paid-in Capital ： NT$ 1.3973375 billion

• Listing Date ： 2012/10/24

==> picture [144 x 33] intentionally omitted <==

5

Company Milestones

==> picture [720 x 339] intentionally omitted <==

----- Start of picture text -----

2016
• IBA first official direct
2014 selling contract signed in
Taiwan
2012 • Greater China
• Announce entering
2009 • Listed in TWSE Sole Distributor Taiwan’s long-term care
for Novadaq
Stock Exchange market
1999 • Founded CHC on Oct 24, 2012
Healthcare Group
• Install the first
Elekta IMRT
2015
1985 linac in Taiwan
2013
• Announce
• Introduced 2011 • Exclsive Distributor for cooperation with
radiotherapy
IBA Proton Therapy Lippo
equipment 2006 • Listed in Taiwan
System
Gretai market as
• Established
Emerging Stock
1997 Ophthalmology
Dept & become • Become distributor • Exclsive Distributor for • Acquired SHIH-LU
• Became sole distributor for for Elekta in South GE Nuclear Medicine &
distributor for Bausch & Lomb China Diagnostic Imaging
1977
Elekta in Taiwan Equipment
• Founded Chiu Ho
Instruments &
Reagent Co., Ltd
6
----- End of picture text -----

Exclusive Distributor for Top Global Brands

Radiation Oncology Imaging System Ophthalmology & Neuroscience

==> picture [236 x 265] intentionally omitted <==

==> picture [118 x 66] intentionally omitted <==

==> picture [204 x 22] intentionally omitted <==

==> picture [97 x 26] intentionally omitted <==

==> picture [69 x 42] intentionally omitted <==

==> picture [90 x 27] intentionally omitted <==

==> picture [58 x 49] intentionally omitted <==

==> picture [103 x 48] intentionally omitted <==

==> picture [100 x 37] intentionally omitted <==

==> picture [46 x 46] intentionally omitted <==

==> picture [93 x 79] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

7

“ Full Service Solution Provider TurnKey Solutions”

==> picture [720 x 295] intentionally omitted <==

----- Start of picture text -----

Manufacturer Technical & Service
Product Strength Strength
Top Global Brands Manufacturers
CHC Healthcare Group
• Certified Service Team
Radiation
• Neuroscience Revenue ．Site Planning
Technical
• Ophthalmology Sharing Direct Selling Services ．Site Construction
Partnerships
• ．
Medical Imaging Operational Consulting
• ．
Surgery Hospital & Clinic Installation
．
Education & Training
．
Maintenance
．
Patient Upgrades
----- End of picture text -----

==> picture [144 x 33] intentionally omitted <==

8

Product Mix

==> picture [290 x 240] intentionally omitted <==

Service Revenue 13% Sales Revenue Revenue 50% Sharing 37% 2015 Annual

Value-Added Business Model

==> picture [144 x 33] intentionally omitted <==

9

==> picture [594 x 124] intentionally omitted <==

==> picture [128 x 124] intentionally omitted <==

==> picture [426 x 236] intentionally omitted <==

----- Start of picture text -----

Operational Future
Q & A
Results Guidance
----- End of picture text -----

==> picture [144 x 33] intentionally omitted <==

10

Big Success in IBA Proton Therapy

CHC signed first official direct selling contract in Taiwan!!!

==> picture [144 x 33] intentionally omitted <==

11

==> picture [117 x 86] intentionally omitted <==

IBA Proton Therapy Unrivalled Experience

30+ 40+ 50,000+ YEARS OF EXPERIENCE PARTNER INSTITUTIONS PATIENTS TREATED MARKET SHARE

==> picture [144 x 33] intentionally omitted <==

12

Proton Design Flexibility

Proteus PLUS

1,800m[2 ]

Proteus ONE

300 m[2 ]

==> picture [144 x 33] intentionally omitted <==

13

==> picture [427 x 208] intentionally omitted <==

IBA Proteus ONE

==> picture [500 x 190] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

14

Pencil Beam Scanning by IBA

==> picture [720 x 288] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

15

==> picture [148 x 28] intentionally omitted <==

Intra-Operative Imaging

==> picture [233 x 290] intentionally omitted <==

==> picture [156 x 293] intentionally omitted <==

SPY

PINPOINT

==> picture [253 x 142] intentionally omitted <==

==> picture [253 x 169] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

16

==> picture [268 x 370] intentionally omitted <==

Applications

==> picture [149 x 29] intentionally omitted <==

• Coronary Artery Bypass Grafting(CABG)

• Cardiovascular Surgery

• Plastic Surgery

• Reconstructive Surgery

• Microsurgery

• Organ Transplantation

• • Gastrointestinal Surgery

==> picture [144 x 33] intentionally omitted <==

17

==> picture [132 x 47] intentionally omitted <==

Elekta - Versa HD

==> picture [144 x 33] intentionally omitted <==

18

High definition by high modulation

• Precisely targeted

• Intelligently controlled

• Quality Assured

==> picture [144 x 33] intentionally omitted <==

19

Corporate Governance

• 2015 Corporate Governance Evaluation

• Ranking between top 21%~35% among all TWSE/TPEx listed companies

• Corporate Social Responsibility Report (CSR Report)

• – Will be published since 2016

CSR Committee

==> picture [523 x 174] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

20

==> picture [594 x 124] intentionally omitted <==

==> picture [128 x 124] intentionally omitted <==

==> picture [127 x 128] intentionally omitted <==

----- Start of picture text -----

Company
Overview
----- End of picture text -----

==> picture [331 x 236] intentionally omitted <==

----- Start of picture text -----

Future
Q & A
Guidance
----- End of picture text -----

==> picture [144 x 33] intentionally omitted <==

21

Entering Long-Term Care Market

==> picture [125 x 34] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

22

==> picture [448 x 233] intentionally omitted <==

==> picture [273 x 49] intentionally omitted <==

MoU Signed with

． ． 2016 10 04

==> picture [720 x 156] intentionally omitted <==

23

Sakurajyuji Group

• Name ： Sakurajyuji Group

==> picture [241 x 93] intentionally omitted <==

• Date of Establish ： 2006/07

• CEO ： Mr. Tomoki Nishikawa

• Number of employees ：About 2,100 people

• Headquarters ： Kumamoto

• Branches ： Kumamoto, Tokyo, Fukuoka, Yatsushiro, Singapore & Philippines

• • Major Business ： Running Hospital and Long-term Care Services Business

==> picture [144 x 33] intentionally omitted <==

24

==> picture [381 x 195] intentionally omitted <==

==> picture [340 x 195] intentionally omitted <==

Elder-Friendly Design

==> picture [144 x 33] intentionally omitted <==

25

==> picture [130 x 47] intentionally omitted <==

Introduce New Product

==> picture [144 x 33] intentionally omitted <==

26

Elekta MR-Linac

==> picture [478 x 300] intentionally omitted <==

==> picture [144 x 33] intentionally omitted <==

27

MR Adaptive RT

Soft Tissue Imaging with Diagnostic Quality + HD Dynamic Radiosurgery

==> picture [144 x 33] intentionally omitted <==

28

Products and Geography Expansion

Existing Products New Products

IBA Proton Therapy Ophthalmology Equipment Neuroscience Equipment Novadaq Fluorescence Imaging Technology (Greater China) Elekta - Linear Accelerator for Taiwan & South China Taiwan Region Expansion GE Nuclear Medicine & Diagnostic Imaging Equipment Cancer Center Consulting & Management (Taiwan、China、Southeast Asia) White Essence Dental Clinic (Exclusive Greater China Distributor) Long-Term Care Business

29

Headquarter in Subsidiary in Beijing Taiwan

Subsidiary in Guangzhou Indonesia

Be the Leading Medical Equipment Full Service Solutions Provider in Asia-Pacific

==> picture [144 x 33] intentionally omitted <==

30

==> picture [594 x 124] intentionally omitted <==

==> picture [128 x 124] intentionally omitted <==

==> picture [127 x 128] intentionally omitted <==

----- Start of picture text -----

Company
Overview
----- End of picture text -----

==> picture [237 x 236] intentionally omitted <==

----- Start of picture text -----

Q & A
----- End of picture text -----

==> picture [144 x 33] intentionally omitted <==

31

==> picture [164 x 108] intentionally omitted <==

==> picture [319 x 104] intentionally omitted <==

==> picture [193 x 103] intentionally omitted <==

==> picture [291 x 107] intentionally omitted <==

==> picture [161 x 102] intentionally omitted <==

Thank you

==> picture [144 x 33] intentionally omitted <==

32